Collegium Pharmaceutical vs Harmony Biosciences
COLL and HRMY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How COLL and HRMY compare
Harmony Biosciences is the larger company, worth 2.5 times as much as Collegium Pharmaceutical ($2.0B against $808M).
On earnings, Harmony Biosciences is cheaper: it trades at 11.3× trailing earnings, against 24.8× for Collegium Pharmaceutical.
Harmony Biosciences grew revenue faster over the last twelve months (19.8% versus 7.7% for Collegium Pharmaceutical).
Harmony Biosciences keeps more of each dollar of sales as profit, with a net margin of 18.1% compared with 4.7% at Collegium Pharmaceutical.
Harmony Biosciences scores higher on the StockData Score (18 against 10 for Collegium Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | COLL | HRMY |
|---|---|---|
| Size and price | ||
| Market cap | $808M | $2.0B |
| Share price | $24.81 | $34.22 |
| Change, 1 year | −43.0% | 7.5% |
| Change, 5 years | 31.6% | −11.7% |
| Beta (5Y) | 0.47 | 0.93 |
| Employees | 423 | 293 |
| StockData Score | ||
| Total score | 10 | 18 (better) |
| Valuation score | 3 | 6 (better) |
| Growth score | 2 | 2 |
| Performance score | 4 | 4 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 24.8× | 11.3× (better) |
| P/S | 1.0× (better) | 2.0× |
| P/B | 2.7× | 1.9× (better) |
| EV/EBITDA | 5.3× (better) | 6.2× |
| P/FCF | 2.4× | – |
| FCF yield | 41.6% | – |
| Fair value | $44.75 | $56.87 |
| Margin of safety | 44.6% (better) | 39.8% |
| Growth | ||
| Revenue growth (TTM) | 7.7% | 19.8% (better) |
| Revenue growth, 5Y average | 20.3% | 40.3% (better) |
| Net income growth (TTM) | −34.7% | −3.8% (better) |
| EPS growth (TTM) | −37.9% | −4.7% (better) |
| EPS growth, 5Y average | 17.9% | – |
| Profitability | ||
| Gross margin | 59.0% | 74.0% (better) |
| Operating margin | 15.2% | 22.2% (better) |
| Net margin | 4.7% | 18.1% (better) |
| FCF margin | 41.3% | – |
| Return on equity | 13.4% | 18.7% (better) |
| Return on invested capital | 160% (better) | 43.1% |
| Financial health | ||
| Debt / equity | – | 0.14 |
| Net debt / EBITDA | – | −2.84 |
| Interest coverage | 1.6× | 17.0× (better) |
| Current ratio | 1.01 | 3.44 (better) |
| Altman Z-score | 0.81 | 4.94 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 121% | 93.0% |
| Held by insiders | 4.3% | 12.1% |
| Insider net buying, 12 months | −$4.4M (better) | −$5.8M |
| Short interest, % of float | 16.7% | 13.0% |
Go deeper
- COLL stock overview
- COLL income statement
- COLL valuation and score
- HRMY stock overview
- HRMY income statement
- HRMY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.